Aesculap: From Products to Process
Like its parent company, B. Braun, Aesculap has built a business around a broad-based offering of products, in this case general and specialty surgical instruments and devices and orthopedic implants. Such a strategy enables Aesculap to leverage everything from product development to sales and marketing. But now, as Aesculap seeks to extend such leveraging to collaborations with its parent company, the company walks a fine line between exploiting natural synergies without sacrificing the focus that made it successful in the first place.
You may also be interested in...
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
BeiGene gets a new chief business executive and there are new CMOs at Cellectar Biopharma, MacroGenics and Reata Pharmaceuticals.
A new EU pilot will help drug regulators and policymakers understand the factors influencing the uneven availability of centrally authorized medicines in the member states.